Schedule 13G ownership disclosure
Zentalis Pharmaceuticals, Inc.
Security class unavailable · CUSIP: 98943L107
Event date: 2022-01-25
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 6.7000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-22-000577
- Form type
- SC 13G
- Filer
- Avidity Partners Management LP
- CIK
- CIK 1791827
- Filed
- Feb 01, 2022
- Reporting period
- Jan 25, 2022
- Description
- Schedule 13G beneficial ownership